Core Insights - The company, Taimei Medical Technology (02576.HK), is undergoing significant developments as of February 13, 2026, including executive changes, project advancements, and performance updates. Group 1: Executive Changes - On January 22, 2026, the board resolved to propose the adoption of the 2026 H-share incentive plan, planning to grant approximately 20.04 million awards to 63 participants, pending shareholder approval at a special general meeting [2]. Group 2: Project Advancements - On December 24, 2025, the company, as a limited partner, established a partnership with other parties with an initial investment of RMB 227 million, of which the company contributed RMB 70 million. This partnership aims to prioritize investments in innovative drug development companies located in the Jiaxing Economic and Technological Development Zone, focusing on early-stage innovative drug pipeline investments through its digital solutions [3]. Group 3: Performance and Operating Conditions - According to the mid-year report for 2025, the company reported a revenue of RMB 244 million for the first half of the year, a decrease of 10.47% year-on-year, with a net loss of RMB 22.802 million, which has narrowed compared to the same period last year. The full-year performance for 2024 showed an adjusted loss reduction of 81.9%, with a gross margin increase of 9.6 percentage points to 40.8% [4]. Group 4: Industry Position - The company ranked first in market share in China's clinical trial information system for the fourth consecutive year in 2024. In 2025, its AI smart body practice was included in the Zhejiang Province artificial intelligence application scenario list, and the Trials intelligent clinical research collaboration platform was recognized as one of the first "Zhejiang Province Manufacturing Single Champion Enterprises" [5].
太美医疗科技股权激励待审议，中期营收下滑亏损收窄